Multiple Approaches to Minimize Transfusions for Pediatric Patients in Open-Heart Surgery

Jae Gun Kwak1, MinKyoung Park2, JinKwon Lee2

  • 1Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Bucheon-Si, Gyeonggi-Do, Republic of Korea. switch.surgeon@gmail.com.

Pediatric Cardiology
|July 25, 2015
PubMed

Insights

Reducing blood transfusions in pediatric open-heart surgery patients using a targeted strategy significantly shortened intensive care unit stays and reduced complications. This approach minimized blood product use without adverse effects, improving patient recovery outcomes.

Area of Science:

  • Pediatric Cardiac Surgery
  • Transfusion Medicine
  • Critical Care

Background:

  • Blood transfusions in pediatric open-heart surgery can lead to complications.
  • Minimizing allogeneic blood exposure is crucial for patient safety and outcomes.

Purpose of the Study:

  • To evaluate a strategy for reducing perioperative blood product use in pediatric patients undergoing open-heart surgery.
  • To assess the impact of reduced transfusion volume on postoperative outcomes.

Main Methods:

  • Retrospective review of 349 pediatric patients (<15 years, ≤30 kg) undergoing open-heart surgery.
  • Strategy included: optimized cardiopulmonary bypass (CPB) priming, routine modified ultrafiltration, and restrictive postoperative red blood cell (RBC) transfusion criteria (hematocrit ≤25%).

Main Results:

  • 23.2% of patients did not require blood products; 34.1% did not receive RBCs in CPB priming.
  • Patients not requiring transfusion had significantly shorter intensive care unit (ICU) stays (0.97 ± 0.5 days vs. 4.1 ± 5.5 days).
  • Reduced transfusion volume correlated with shorter ventilator support, ICU/hospital stays, and decreased inflammatory and kidney injury markers.

Conclusions:

  • The implemented strategy effectively reduced blood transfusion volumes in pediatric open-heart surgery.
  • This approach led to improved postoperative outcomes, including shorter ICU stays and reduced complications.
  • Lower hematocrit levels within the study parameters did not result in observed adverse events.